Mode
Text Size
Log in / Sign up
Phase 3 N=30 Randomized Double-blind Treatment

Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald)

Myopia

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Sep 2010
Primary outcome: Primary: High Contrast Visual Acuity — -0.04; -0.04 logMAR

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
ClearCare (Drug); Optifree Replenish (Drug)
Age
Pediatric, Adult, Older Adult · 17+ yrs
Sex
All
Sponsor
University of Waterloo
Primary completion
Dec 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
High Contrast Visual Acuity
-0.04; -0.04
PRIMARY
Low Contrast Visual Acuity
0.26; 0.25
PRIMARY
In-vivo Wettability
7.06; 6.54
PRIMARY
Subjective Comfort Rating
82.5; 81.3

Summary

The purpose of the study is to evaluate and compare, on a daily wear basis, the performance of two contact lens care solutions when used with silicone hydrogel soft contact lenses with regards to comfort and dryness symptoms.

Eligibility Criteria

Inclusion Criteria

A person is eligible for inclusion in the study if he/she:

  • Is at least 17 years of age and has full legal capacity to volunteer.
  • Has read, understood and signed an information consent letter.
  • Is willing and able to follow instructions and maintain the appointment schedule.
  • Is presently using either bi-weekly or monthly replacement lenses.
  • Has symptoms of ocular dryness as determined by specific pre-screening criteria.
  • Is correctable to a visual acuity of 6/9 or better (in each eye) with their habitual vision correction.
  • Has clear corneas and no active ocular disease.
  • Has had an ocular examination in the last two years.

Exclusion Criteria

A person will be excluded from the study if he/she:

  • Is an asymptomatic lens wearer.
  • Is a daily disposable contact lens wearer.
  • Is a current extended wear contact lens wearer.
  • Currently uses one of the study lens care regimens.
  • Has any clinically significant blepharitis.
  • Has undergone corneal refractive surgery.
  • Is aphakic.
  • Has any active ocular disease.
  • Has any systemic disease affecting ocular health.
  • Is using any systemic or topical medications that may affect ocular health.
  • Has known sensitivity to the diagnostic pharmaceuticals to be used in the study.
  • Is participating in any other type of clinical or research study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00520351). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search